Maze Therapeutics, Inc. (MAZE)

NASDAQ: MAZE · Real-Time Price · USD
11.32
-0.66 (-5.51%)
Feb 13, 2025, 4:00 PM EST - Market closed
-5.51%
Market Cap 495.56M
Revenue (ttm) 167.50M
Net Income (ttm) -18.27M
Shares Out 43.78M
EPS (ttm) -0.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 339,551
Open 12.13
Previous Close 11.98
Day's Range 10.92 - 12.45
52-Week Range 10.92 - 17.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About MAZE

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidn... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2025
Employees 121
Stock Exchange NASDAQ
Ticker Symbol MAZE
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop nove...

6 days ago - GlobeNewsWire

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK T...

12 days ago - Seeking Alpha

Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut

Shares of Maze Therapeutics rose nearly 1% in their Nasdaq debut on Friday, valuing the kidney disease drug developer at $690.37 million.

13 days ago - Reuters

Biotech firm Maze Therapeutics raises $140 million in US IPO

Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that could make the kidney disease drug developer the first U.S. biotech lis...

14 days ago - Reuters

Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop nove...

14 days ago - GlobeNewsWire

Maze Therapeutics targets up to $728 mln valuation in US IPO

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States.

17 days ago - Reuters

Maze Therapeutics Seeks IPO For Trials Ramp-Up

Maze Therapeutics aims to raise $100 million in an IPO to fund clinical trials for its kidney and related disease treatments. The company's lead candidate, MZE829, is in Phase 2 trials for APOL1 kidne...

4 weeks ago - Seeking Alpha

Third Rock-backed Maze Therapeutics reveals profit in US IPO filing

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its paperwork for a U.S. initial public offering (IPO) filing on Tuesday.

5 weeks ago - Reuters

Maze Therapeutics looks for IPO lodestar to guide kidney disease assets through clinical trials

Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to boost its kidney disease candidates further by going public.

5 weeks ago - Fierce Biotech

Maze Therapeutics IPO Registration Document (S-1)

Maze Therapeutics has filed to go public with an IPO on the NASDAQ.

5 weeks ago - SEC